The interest for krill-based ingredients for aquaculture feed applications has increased steadily in recent years. For decades, there has been a heavy reliance on the limited sources of fishmeal and fish oil in the salmonid aquaculture industry. Further growth in farming of carnivorous fish is dependent on new feed resources becoming available. The only unexploited marine resources of significant biomass are found at lower trophic levels, of which the Antarctic krill (Euphausia superba) has a high potential. Apart from being the biggest single species biomass, Antarctic krill is also rich in nutrients, such as omega-3 polyunsaturated fatty acids, phospholipids, astaxanthin, vitamins, and minerals. This makes Antarctic krill a high-quality source of health-beneficial lipids and proteins. The present article provides an overview on the documented benefits of feeding salmonids (Atlantic salmon (Salmo salar) and rainbow trout (Oncorhynchus mykiss)) with krill products (krill meal, krill oil, and krill hydrolysate), focusing on growth performance (feed intake, growth rate, and feed conversion), fillet quality, slaughter yield, and health benefits in terms of reducing fat accumulation in liver and intestinal tissues. Besides, the article discusses possible future studies, to widen the knowledge on krill benefits in salmonids and to unravel the underlying mechanisms.
Intestinal steatosis, called lipid malabsorption syndrome (LMS) in severe cases, is a common condition in farmed Atlantic salmon, associated with choline deficiency causing low lipid transport in enterocytes, excessive lipid accumulation, and increased mucosal weight. A previous dose-response study supplying a plant-based diet with choline chloride indicated that 3.4 g/kg choline prevents LMS in Atlantic salmon. However, no similar documentation exists using phosphatidylcholine (PC) as a choline source. The present study therefore aimed to determine the ability of PC from krill meal (KM) and krill oil (KO) towards reducing steatosis in Atlantic salmon. Two diets with suboptimal PC levels (1.5 and 2.6 g/kg) were tested against two control diets, a choline-deficient diet with no supplementation (0.6 g/kg), and a high choline (4.0 g/kg choline chloride) diet. After 8 weeks of freshwater feeding, growth was significantly higher in KM and KO groups, at both PC levels, in comparison to the choline-deficient group. However, growth was significantly higher only in the KM and KO diets with 2.6 g/kg of PC when compared to the positive control. This indicated that suboptimal levels of PC from KM and KO satisfied choline needs for growth. A clear dose-dependent effect on the decreasing pyloric intestine (PI) somatic index was observed for KM and KO diets, with no significant difference between KM and KO diets (2.6 g/kg choline) and high choline reference diet. Accordingly, PC from both KM and KO significantly reduced lipid accumulation in the PI and liver when added to a choline-deficient diet. However, histological and lipid analyses also indicated that the optimal dietary choline requirement for full elimination of lipid accumulation in PI is higher than 2.6 g/kg with KM and KO as supplementary sources.
Growth and histological parameters were evaluated in Atlantic salmon (74 g) that were fed alternative phospholipid (PL) sources in freshwater (FW) up to 158 g and were transferred to a common seawater (SW) tank with crowding stress after being fed the same commercial diet up to 787 g. There were six test diets in the FW phase: three diets with different doses of krill meal (4%, 8%, and 12%), a diet with soy lecithin, a diet with marine PL (from fishmeal), and a control diet. The fish were fed a common commercial feed in the SW phase. The 12% KM diet was compared against the 2.7% fluid soy lecithin and 4.2% marine PL diets, which were formulated to provide the same level of added 1.3% PL in the diet similar to base diets with 10% fishmeal in the FW period. A trend for increased weight gain with high variability was associated with an increased KM dose in the FW period but not during the whole trial, whereas the 2.7% soy lecithin diet tended to decrease growth during the whole trial. A trend for decreased hepatosomatic index (HSI) was associated with an increased KM dose during transfer but not during the whole trial. The soy lecithin and marine PL diets showed similar HSI in relation to the control diet during the whole trial. No major differences were observed in liver histology between the control, 12% KM, soy lecithin, and marine PL diets during transfer. However, a minor positive trend in gill health (lamella inflammation and hyperplasia histology scores) was associated with the 12% KM and control diets versus the soy lecithin and marine PL diets during transfer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.